Literature DB >> 17154312

Cell-free synthesis of proteins that require disulfide bonds using glucose as an energy source.

Kurtis G Knapp1, Aaron R Goerke, James R Swartz.   

Abstract

The primary objective of this work was to create a cell-free protein synthesis extract that produces proteins requiring disulfide bonds while using glucose as an energy source. We attempted to avoid using iodoacetamide (IAM) to stabilize the required oxidizing thiol redox potential, since previous IAM pretreatments prevented glucose utilization apparently by inactivating glyceraldehyde 3-phosphate dehydrogenase (G-3PDH). Instead, the glutathione reductase (Gor)-mediated disulfide reductase system was disabled by deleting the gor gene from the KC6 cell-extract source strain. The thioredoxin reductase (TrxB)-mediated system was disabled by first adding a purification tag to the trxB gene in the chromosome to create strain KGK10 and then by affinity removal of the tagged TrxB. This was expected to result in a cell extract devoid of all disulfide reductase activity, but this was not the case. Although the concentration of IAM required to stabilize oxidized glutathione in the KGK10 extract could be reduced 20-fold, IAM pretreatment was still required to avoid disulfide reduction. Nonetheless, active urokinase and murine granulocyte macrophage-colony stimulating factor (mGM-CSF) were produced in reactions with KGK10 extract either with affinity removal of TrxB or with 50 microM IAM pretreatment. With the less intensive IAM pretreatment, glucose could be used as an energy source in a production system that promotes oxidative protein folding. This new protocol offers an economically feasible cell-free system for the production of secreted mammalian proteins as human therapeutics or vaccines. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17154312     DOI: 10.1002/bit.21296

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  8 in total

1.  pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.

Authors:  Pete Heinzelman; Jennifer A Schoborg; Michael C Jewett
Journal:  Protein Eng Des Sel       Date:  2015-04-15       Impact factor: 1.650

2.  Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry.

Authors:  Kedar G Patel; James R Swartz
Journal:  Bioconjug Chem       Date:  2011-02-28       Impact factor: 4.774

Review 3.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.

Authors:  Chung-Jr Huang; Henry Lin; Xiaoming Yang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-01-18       Impact factor: 3.346

Review 4.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

5.  Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells.

Authors:  Kedar G Patel; Patrick P Ng; Chiung-Chi Kuo; Shoshana Levy; Ronald Levy; James R Swartz
Journal:  Biochem Biophys Res Commun       Date:  2009-10-21       Impact factor: 3.575

Review 6.  Cell-free protein synthesis: the state of the art.

Authors:  James W Whittaker
Journal:  Biotechnol Lett       Date:  2012-10-21       Impact factor: 2.461

7.  Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines.

Authors:  James F Zawada; Gang Yin; Alexander R Steiner; Junhao Yang; Alpana Naresh; Sushmita M Roy; Daniel S Gold; Henry G Heinsohn; Christopher J Murray
Journal:  Biotechnol Bioeng       Date:  2011-03-31       Impact factor: 4.530

Review 8.  Synthetic Glycobiology: Parts, Systems, and Applications.

Authors:  Weston Kightlinger; Katherine F Warfel; Matthew P DeLisa; Michael C Jewett
Journal:  ACS Synth Biol       Date:  2020-06-30       Impact factor: 5.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.